Literature DB >> 23237009

Gene × environment interactions in the prediction of response to antidepressant treatment.

Torsten Klengel1, Elisabeth B Binder.   

Abstract

Major depressive disorder (MDD) is responsible for an increasing individual and global health burden. Extensive research on the genetic disposition to develop MDD and to predict the response to antidepressant treatment has yet failed to identify strong genetic effects. The concept of gene × environment interaction takes into account that environmental factors have been identified as important components in the development of MDD and combines both, genetic predisposition and environmental exposure, to elucidate complex traits such as MDD. Here, we review the current research on gene × environment interactions with regard to the development of MDD as well as response to antidepressant treatment. We hypothesize that gene × environment interactions delineate specific biological subtypes of depression and that individuals with such pathophysiological distinct types of depression will likely respond to different treatments. The elucidation of gene × environment interactions may thus not only help to understand the pathophysiology of MDD but could also provide markers for a personalized antidepressant therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23237009     DOI: 10.1017/S1461145712001459

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  9 in total

Review 1.  Issues on the diagnosis and etiopathogenesis of mood disorders: reconsidering DSM-5.

Authors:  Kazuyoshi Ogasawara; Yukako Nakamura; Hiroyuki Kimura; Branko Aleksic; Norio Ozaki
Journal:  J Neural Transm (Vienna)       Date:  2017-12-23       Impact factor: 3.575

2.  [Significance of the German Act on the Reform of the Market for Medicinal Products for psychopharmacotherapy].

Authors:  G Gründer
Journal:  Nervenarzt       Date:  2016-04       Impact factor: 1.214

3.  Leukocyte telomere length predicts SSRI response in major depressive disorder: A preliminary report.

Authors:  Christina M Hough; F Saverio Bersani; Synthia H Mellon; Elissa S Epel; Victor I Reus; Daniel Lindqvist; Jue Lin; Laura Mahan; Rebecca Rosser; Heather Burke; John Coetzee; J Craig Nelson; Elizabeth H Blackburn; Owen M Wolkowitz
Journal:  Mol Neuropsychiatry       Date:  2016-06-22

4.  Epigenetic landscape of stress surfeit disorders: Key role for DNA methylation dynamics.

Authors:  Eleonora Gatta; Vikram Saudagar; James Auta; Dennis R Grayson; Alessandro Guidotti
Journal:  Int Rev Neurobiol       Date:  2020-09-30       Impact factor: 3.230

Review 5.  Stress, Inflammation, and Cellular Vulnerability during Early Stages of Affective Disorders: Biomarker Strategies and Opportunities for Prevention and Intervention.

Authors:  Adam J Walker; Yesul Kim; J Blair Price; Rajas P Kale; Jane A McGillivray; Michael Berk; Susannah J Tye
Journal:  Front Psychiatry       Date:  2014-04-09       Impact factor: 4.157

Review 6.  Stress Response and Perinatal Reprogramming: Unraveling (Mal)adaptive Strategies.

Authors:  Laura Musazzi; Jordan Marrocco
Journal:  Neural Plast       Date:  2016-03-16       Impact factor: 3.599

Review 7.  Prognosis and improved outcomes in major depression: a review.

Authors:  Christoph Kraus; Bashkim Kadriu; Rupert Lanzenberger; Carlos A Zarate; Siegfried Kasper
Journal:  Transl Psychiatry       Date:  2019-04-03       Impact factor: 6.222

Review 8.  Telemonitoring with respect to mood disorders and information and communication technologies: overview and presentation of the PSYCHE project.

Authors:  Hervé Javelot; Anne Spadazzi; Luisa Weiner; Sonia Garcia; Claudio Gentili; Markus Kosel; Gilles Bertschy
Journal:  Biomed Res Int       Date:  2014-06-24       Impact factor: 3.411

9.  S100B Serum Levels Predict Treatment Response in Patients with Melancholic Depression.

Authors:  Oliver Ambrée; Veerle Bergink; Laura Grosse; Judith Alferink; Hemmo A Drexhage; Matthias Rothermundt; Volker Arolt; Tom K Birkenhäger
Journal:  Int J Neuropsychopharmacol       Date:  2015-09-12       Impact factor: 5.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.